Orabi-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the amplitude of gastric contractions and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these agents in Orabi-DSR Capsule addresses both the symptomatic and pathophysiological aspects of acid-related gastrointestinal disorders. This combination is particularly beneficial in patients presenting with reflux symptoms accompanied by delayed gastric emptying or dysmotility. Orabi-DSR should be administered under medical supervision, with dosage and duration tailored to individual patient needs. Caution is advised in patients with known hypersensitivity to either component, and potential drug interactions should be considered. Regular monitoring is recommended to assess therapeutic efficacy and detect any adverse effects.